Key Points
- Director Lynnette Fallon sold 5,091 shares of ClearPoint Neuro at an average price of $11.14, reducing her ownership by about 9.55% and leaving her with 48,227 shares.
- ClearPoint Neuro recently reported a loss of $0.32 per share, missing analyst expectations, though quarterly revenue of $12.13 million came in slightly above estimates.
- Analyst views are mixed but lean cautious: recent ratings include two Buy calls and one Sell, with MarketBeat showing a consensus Hold and a $18.00 target price.
ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) Director Lynnette Fallon sold 5,091 shares of the business's stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $11.14, for a total transaction of $56,713.74. Following the sale, the director owned 48,227 shares in the company, valued at $537,248.78. The trade was a 9.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
ClearPoint Neuro Stock Performance
NASDAQ:CLPT opened at $11.70 on Friday. The firm's fifty day simple moving average is $10.56 and its 200-day simple moving average is $12.80. The company has a quick ratio of 4.88, a current ratio of 5.79 and a debt-to-equity ratio of 2.63. The stock has a market cap of $350.88 million, a PE ratio of -11.58 and a beta of 1.29. ClearPoint Neuro, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $30.10.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The company had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. Analysts expect that ClearPoint Neuro, Inc. will post -1.05 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on CLPT. Stifel Nicolaus began coverage on ClearPoint Neuro in a research note on Friday, May 8th. They set a "buy" rating and a $16.00 price target on the stock. B. Riley Financial raised their price objective on ClearPoint Neuro from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, March 18th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ClearPoint Neuro in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, ClearPoint Neuro currently has a consensus rating of "Hold" and a consensus target price of $18.00.
Check Out Our Latest Research Report on ClearPoint Neuro
Hedge Funds Weigh In On ClearPoint Neuro
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLPT. Caitong International Asset Management Co. Ltd purchased a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $25,000. Huntington National Bank acquired a new position in shares of ClearPoint Neuro during the 3rd quarter worth approximately $44,000. BNP Paribas Financial Markets raised its position in shares of ClearPoint Neuro by 2,435.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company's stock worth $27,000 after purchasing an additional 2,143 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in ClearPoint Neuro by 1,079.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company's stock valued at $51,000 after buying an additional 2,158 shares in the last quarter. Finally, Legal & General Group Plc purchased a new stake in ClearPoint Neuro in the 2nd quarter valued at approximately $35,000. Institutional investors and hedge funds own 30.08% of the company's stock.
About ClearPoint Neuro
(
Get Free Report)
ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company's flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.
The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
